Search
Tubocurarine
go.drugbank.com/drugs/DB01199ApprovedWithdrawn[A216048] Safer and more pharmacokinetically favorable non-depolarizing neuromuscular blockers, such as [rocuronium], have largely replaced the use of tubocurarine in the clinical setting.[A216048] … [A216028] It was first isolated by Harold King in 1935 and was used clinically to induce neuromuscular blockade during surgeries, particularly those involving the abdomen.
Golimumab
go.drugbank.com/drugs/DB06674ApprovedInvestigationalIn the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. … Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate
Products: SIMPONI 50MG ILO I E FER, SIMPONI SOLUTION FOR INJECTION IN PRE-FILLED PEN 45MG/0.45MLMethadone
go.drugbank.com/drugs/DB00333ApprovedInvestigational[A185876] Compared to other opioids, methadone's effects on NMDA inhibition may explain it's improved analgesic efficacy and reduced opioid tolerance. … [A185888,A185891,A185897] Compared with [morphine], the gold standard reference opioid, methadone also acts as an agonist of κ- and σ-opioid receptors, as an antagonist of the N-methyl-D-aspartate (NMDA
Categories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersDamoctocog alfa pegol
go.drugbank.com/drugs/DB14700ApprovedInvestigational[L4576,A38909] This product has been engineered by Bayer[L4576] and a biological license application has been filed with the FDA in August 2017 and FDA approved in August 2018.[F1609] … In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor. … Rheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases.
Mometasone furoate
go.drugbank.com/drugs/DB14512ApprovedInvestigationalVet approvedMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label] . It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and highe...
Technetium Tc-99m nofetumomab merpentan
go.drugbank.com/drugs/DB09336ApprovedWithdrawn[FDA label] Tc-99m nm was developed by Boehringer Ingelheim Pharma KG and FDA approved on September 14, 1992. … It was after discontinued on August 13, 2013, but in the 2018 FDA submission list, it can be found as a substance type II (Drug substance) with an active status.[L1650, L1082]
Hemin
go.drugbank.com/drugs/DB03404ApprovedInvestigationalHemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand.
Sulfathiazole
go.drugbank.com/drugs/DB06147ApprovedVet approvedWithdrawnIt is still occasionally used, sometimes in combination with sulfabenzamide and sulfacetamide.
Mixtures: STREPTOSIL CON NEOMICINA, STREPTOSIL CON NEOMICINASynonyms: N(1)-2-Thiazolylsulfanilamide, 4-Amino-N-2-thiazolylbenzenesulfonamideBrepocitinib
go.drugbank.com/drugs/DB15003ApprovedInvestigational[L64097] The FDA approved brepocitinib on August 27, 2026 for the treatment of dermatomyositis in adult patients, making it the first targeted oral therapy approved for the condition.[L64115] … Brepocitinib is an oral Janus kinase (JAK) and tyrosine kinase 2 (TYK2) inhibitor used to treat dermatomyositis in adults.